203 related articles for article (PubMed ID: 34929693)
1. Chemoprevention of Oesophageal Squamous-Cell Carcinoma and Adenocarcinoma: A Multicentre Retrospective Cohort Study.
Arai J; Niikura R; Hayakawa Y; Kawahara T; Honda T; Hasatani K; Yoshida N; Nishida T; Sumiyoshi T; Kiyotoki S; Ikeya T; Arai M; Suzuki N; Tsuji Y; Yamada A; Kawai T; Koike K
Digestion; 2022; 103(3):192-204. PubMed ID: 34929693
[TBL] [Abstract][Full Text] [Related]
2. NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study.
Masclee GM; Coloma PM; Spaander MC; Kuipers EJ; Sturkenboom MC
BMJ Open; 2015 Jan; 5(1):e006640. PubMed ID: 25633286
[TBL] [Abstract][Full Text] [Related]
3. Association of Common Use Pharmaceuticals in Reducing Risk of Esophageal Adenocarcinoma: A SEER-Medicare Analysis.
Loomans-Kropp HA; Chaloux M; Richmond E; Umar A
Cancer Prev Res (Phila); 2021 Feb; 14(2):195-204. PubMed ID: 32998939
[TBL] [Abstract][Full Text] [Related]
4. Current Status of Chemoprevention in Barrett's Esophagus.
Moayyedi P; El-Serag HB
Gastrointest Endosc Clin N Am; 2021 Jan; 31(1):117-130. PubMed ID: 33213791
[TBL] [Abstract][Full Text] [Related]
5. Statin use is associated with reduced risk of histologic subtypes of esophageal cancer: a nested case-control analysis.
Alexandre L; Clark AB; Bhutta HY; Holt S; Lewis MP; Hart AR
Gastroenterology; 2014 Mar; 146(3):661-8. PubMed ID: 24315828
[TBL] [Abstract][Full Text] [Related]
6. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus.
Nguyen DM; Richardson P; El-Serag HB
Gastroenterology; 2010 Jun; 138(7):2260-6. PubMed ID: 20188100
[TBL] [Abstract][Full Text] [Related]
7. Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett's oesophagus: a nested case-control study in US male veterans.
Tan MC; El-Serag HB; Yu X; Thrift AP
Aliment Pharmacol Ther; 2018 Aug; 48(4):469-477. PubMed ID: 29956826
[TBL] [Abstract][Full Text] [Related]
8. Statin use reduces risk of esophageal adenocarcinoma in US veterans with Barrett's esophagus: a nested case-control study.
Nguyen T; Duan Z; Naik AD; Kramer JR; El-Serag HB
Gastroenterology; 2015 Nov; 149(6):1392-8. PubMed ID: 26208896
[TBL] [Abstract][Full Text] [Related]
9. Statin use is associated with a reduction in the incidence of esophageal adenocarcinoma: a case control study.
Beales IL; Vardi I; Dearman L; Broughton T
Dis Esophagus; 2013; 26(8):838-46. PubMed ID: 22989236
[TBL] [Abstract][Full Text] [Related]
10. Statins and aspirin for chemoprevention in Barrett's esophagus: results of a cost-effectiveness analysis.
Choi SE; Perzan KE; Tramontano AC; Kong CY; Hur C
Cancer Prev Res (Phila); 2014 Mar; 7(3):341-50. PubMed ID: 24380852
[TBL] [Abstract][Full Text] [Related]
11. Regular statin and aspirin use in patients with Barrett's oesophagus is associated with a reduced incidence of oesophageal adenocarcinoma.
Beales IL; Vardi I; Dearman L
Eur J Gastroenterol Hepatol; 2012 Aug; 24(8):917-23. PubMed ID: 22569083
[TBL] [Abstract][Full Text] [Related]
12. Etiology and risk factors for oesophageal adenocarcinoma: possibilities for chemoprophylaxis?
Lagergren J
Best Pract Res Clin Gastroenterol; 2006; 20(5):803-12. PubMed ID: 16997162
[TBL] [Abstract][Full Text] [Related]
13. Gastro-oesophageal reflux symptoms and the risks of oesophageal cancer: are the effects modified by smoking, NSAIDs or acid suppressants?
Pandeya N; Webb PM; Sadeghi S; Green AC; Whiteman DC;
Gut; 2010 Jan; 59(1):31-8. PubMed ID: 19875392
[TBL] [Abstract][Full Text] [Related]
14. Chemoprevention for Colorectal Cancers: Are Chemopreventive Effects Different Between Left and Right Sided Colorectal Cancers?
Arai J; Suzuki N; Niikura R; Ooki D; Kawahara T; Honda T; Hasatani K; Yoshida N; Nishida T; Sumiyoshi T; Kiyotoki S; Ikeya T; Arai M; Ishibashi R; Aoki T; Tsuji Y; Yamamichi N; Hayakawa Y; Fujishiro M
Dig Dis Sci; 2022 Nov; 67(11):5227-5238. PubMed ID: 35230578
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of chemoprevention with proton pump inhibitors in Barrett's esophagus.
Sharaiha RZ; Freedberg DE; Abrams JA; Wang YC
Dig Dis Sci; 2014 Jun; 59(6):1222-30. PubMed ID: 24795040
[TBL] [Abstract][Full Text] [Related]
16. Additional Benefits of Routine Drugs on Gastrointestinal Cancer: Statins, Metformin, and Proton Pump Inhibitors.
Joo MK; Park JJ; Chun HJ
Dig Dis; 2018; 36(1):1-14. PubMed ID: 28881340
[TBL] [Abstract][Full Text] [Related]
17. Esophageal Adenocarcinoma: The Influence of Medications Used to Treat Comorbidities on Cancer Prognosis.
Thrift AP
Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2225-32. PubMed ID: 25835331
[TBL] [Abstract][Full Text] [Related]
18. Barrett's esophagus and esophageal adenocarcinoma in adults: long-term GERD or something else?
Pondugula K; Wani S; Sharma P
Curr Gastroenterol Rep; 2007 Dec; 9(6):468-74. PubMed ID: 18377797
[TBL] [Abstract][Full Text] [Related]
19. The Epidemiology of Esophageal Adenocarcinoma.
Coleman HG; Xie SH; Lagergren J
Gastroenterology; 2018 Jan; 154(2):390-405. PubMed ID: 28780073
[TBL] [Abstract][Full Text] [Related]
20. Systematic review: the chemoprevention of oesophageal adenocarcinoma.
Mehta S; Johnson IT; Rhodes M
Aliment Pharmacol Ther; 2005 Nov; 22(9):759-68. PubMed ID: 16225483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
